{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.8","upperLimit":"34.4","value":"18.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"Time from start of treatment until date of documented disease progression, removal from protocol due to toxicity, or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bortezomib 1.3 mg/m2 days 1, 8, 15, 22; Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23; Melphalan 9 mg/m2/day days 1-4\n\nbortezomib: Bortezomib 1.3 mg/m2 days 1, 8, 15, 22\n\ndexamethasone: Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23\n\nmelphalan: Melphalan 9 mg/m2/day days 1-4\n\nmicroarray analysis: ≤28 days prior to enrollment\n\nflow cytometry: Day 1 of cycles 6, 12, 18 and at end of study.\n\nlaboratory biomarker analysis: ≤28 days prior to enrollment\n\nquality-of-life assessment: Start of each cycle","id":"OG000","title":"Melphalan, Dexamethasone, Bortezomib,"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"start of treatment until 72 months","title":"Time to Treatment Failure (TTF)","type":"SECONDARY","unitOfMeasure":"month"}